Spider Rock Advisors, LLC Biomarin Pharmaceutical Inc Put Options Transaction History

Spider Rock Advisors, LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 Apr 30, 2024	SELL	$83.81 - $99.0 $58,667 - $69,300	-700 Reduced 10.77%	5,800 $506,000
Q3 2023 Oct 25, 2023	SELL	$85.07 - $94.48 $25,520 - $28,344	-300 Reduced 4.41%	6,500 $614,000
Q1 2023 Apr 24, 2023	SELL	$87.74 - $117.27 $8,774 - $11,727	-100 Reduced 1.45%	6,800 $644,000
Q4 2022 Feb 07, 2023	SELL	$80.93 - $108.63 $32,372 - $43,452	-400 Reduced 5.48%	6,900 $518,000
Q3 2022 Nov 04, 2022	SELL	$82.16 - $96.94 $49,296 - $58,164	-600 Reduced 7.59%	7,300 $548,000
Q1 2022 May 06, 2022	SELL	$74.28 - $92.69 $14,856 - $18,538	-200 Reduced 2.47%	7,900 $592,000
Q3 2021 Oct 19, 2021	SELL	$74.77 - $85.47 $52,339 - $59,829	-700 Reduced 7.95%	8,100 $542,000
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $700,040 - $1.09 Million	-8,800 Reduced 50.0%	8,800 $21,000
Q1 2020 May 11, 2020	BUY	$71.37 - $96.85 $570,960 - $774,800	8,000 Added 83.33%	17,600 $118,000
Q2 2019 Jul 29, 2019	BUY	$80.35 - $93.9 $771,360 - $901,440	9,600 New	9,600 $33,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Spider Rock Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Spider Rock Advisors, LLC with notifications on news.